Volume : 11, Issue : 09, September – 2024
Title:
BUCCAL DRUG DELIVERY APPROACH ANTI-LIPIDEMIC PRAVASTATIN IN THE FORMULATION OF PATCH USING VARIOUS POLYMERS
Authors :
M. MANVITHA*, Dr. KOTRA CHANDRA SEKHAR RANGAIAH
Abstract :
Mucoadhesive buccal patches of Pravastatin were prepared using different polymers like Eudragit RSPO, HPMC and Carbopol in various proportion and combinations by solvent casting method.
The patches were evaluated for their physical characteristics like thickness, folding endurance, water uptake, bioadhesive strength, drug content uniformity, surface pH, Mechanical strength, Scanning electron microscopy (SEM), In-vitro release study, Invitro residence time study and Kinetic study.
The results obtained showed no physical-chemical incompatibility between the drug and the polymers. F6 formulation has been selected as the best formulation among all the other formulations. The in-vitro drug diffusion studies from the formulation were found to be sustained release. All the evaluation parameters obtained from the best formulation were found to be satisfactory. The data obtained from the in-vitro release studies were fitted to various kinetic models like zero order, first order, Higuchi model and peppas model. From the kinetic data it was found that drug release follows zero order release kinetics model release by diffusion technique from the polymer.
Keywords: Pravastatin, Eudragit RSPO, HPMC, Carbopol and Mucoadhesive buccal patch.
Cite This Article:
Please cite this article in press M. Manvitha et al Buccal Drug Delivery Approach Anti-Lipidemic Pravastatin In The Formulation Of Patch Using Various Polymers..,Indo Am. J. P. Sci, 2024; 11 (9).
Number of Downloads : 10
References:
1. Shidhaye SS et al: Mucoadhesive bilayered patches for administration of sumatriptan. AAPS pharm sci tech 2009: 9(3);1-13.
2. Giradkar KP et al: Design development and in vitro evaluation of bioadhesive dosage form for buccal route. International journal of pharma research & development 2010: 2;1-24.
3. Shojaei Amir H., Buccal Mucosa As A Route For Systemic Drug Delivery: A Review, J Pharm PharmaceutSci, 1998;1 (1):15-30.
4. . RC Diojad , FV Manvi ,V Malleshwarrao ,.Buccoadhesive Drug Delivery System Of Isosorbide Dinitrite,Formulation And Evaluation, Ind J Phram Sci,68(2008)744-748.
5. Thimmasetty J, Subramanyam CVS, Manish kumar DS, Manjunath K, Shivanand K. Design and evaluation of fexofenadine HCl buccal mucoadhesive patches. Biomed. 2007; 2(1):73-83.
6. Güneşm Karavana SY,Algin Yapar E.Buccal drug delivery system: an overview about dosage forms and recent studies. Universal Journal of Pharmaceutical Research. 2019; 4(6):69-74.
7. Amir HS. Buccal mucosa as a route for systemic drug delivery: A Review. J Pharm Pharmaceu Sci 1998; 1(1):15-30.
8. Steward A et al, The Effect of Enhancers on the Buccal Absorption of Hybrid (BDBB) Alpha Interferon, Int. J. Pharm, 104, 1994, 145–149.
9. Aungst BJ and Rogers NJ, Site Dependence of Absorption- Promoting Actions of Laureth9, Na Salicylate, Na2EDTA, and Aprotinin on Rectal, Nasal, and Buccal Insulin Delivery, Pharm. Res, 1988, 5 (5), 305–308.
10. Kumar M et al, Design and in vitro evaluation of mucoadhesive buccal films containing Famotidine.
11. FC Carvalho ,ML Bruschi ,RC Evangelista , Mucoadhesive Drug Delivery System, Brazilian Journal Of Pharmaceutical Sciences,4( 2010) 1-17.
12. Y Huang ,W Leobandung , A Foss ,NA Peppas , Molecular Aspects Of Muco And Bioadhesion: Tethered Structures And Site-Specific Surfaces, Journal Of Controlled Release, 65(2000) 63-71.
13. M.M.Veillard et al., “Preliminary Studies of Oral Mucosal Delivery of Peptide Drugs,” J. Controlled Release 6, (1987), 123–131 .
14. A.J. Hoogstraate et al., “Diffusion Rates and Transport Pathways of FITC-Labelled Model Compounds through Buccal Epithelium,” Proc. Int. Symp. Contr. Rel. Bioact.Mater. 20, (1993),234–235.
15. A. Steward et al., “The Effect of Enhancers on the Buccal Absorption of Hybrid (BDBB) AlphaInterferon,” Int. J. Pharm. 104, (1994),145–149 .